Home > Publications database > Pediatric spinal high-grade glioma in the pediatric precision oncology registry INFORM: identification of potential therapeutic targets > print

001     294929
005     20250403112514.0
024 7 _ |a 10.1093/noajnl/vdae185
|2 doi
024 7 _ |a 2632-2498
|2 ISSN
024 7 _ |a altmetric:173828246
|2 altmetric
024 7 _ |a pmid:39896072
|2 pmid
037 _ _ |a DKFZ-2024-02636
082 _ _ |a 610
100 1 _ |a Pfaff, Elke
|0 P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb
|b 0
|e First author
|u dkfz
245 _ _ |a Pediatric spinal high-grade glioma in the pediatric precision oncology registry INFORM: identification of potential therapeutic targets
260 _ _ |a Oxford
|c 2025
|b Oxford University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1738658972_8588
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B360#LA:B360# / Volume 7, Issue 1, January-December 2025, vdae185
520 _ _ |a Background: High-grade glioma (HGG) of the spinal cord constitute rare tumors in the pediatric population. Knowledge of the molecular profile of this pediatric HGG (pedHGG) subgroup is limited and the clinical outcome is poor. Therefore, the aim of this study is to provide more profound investigations of molecular characteristics and clinical features of these tumors. Methods: Between 01/2015 and 10/2023 seventeen spinal tumors with HGG histology were analyzed by the INFORM precision oncology registry. Comprehensive molecular profiling (including next-generation sequencing approaches and DNA methylation analysis) was performed. Clinical data provided by the treating centers was evaluated regarding treatment approaches and outcome. Results: Subgroup classification based on DNA methylation analysis revealed molecular HGG subgroups in 12/17 cases, while 2/17 were classified as molecular low-grade glioma (LGG) and 3/17 were not unequivocally classifiable. Typical genetic alterations described in pedHGG usually presenting at other localizations were also present in the counterparts located in the spinal cohort. Alterations which might serve as promising target for personalized therapy approaches were identified in a subset of tumors.Conclusion: With this cohort of 12 molecularly confirmed spinal pedHGG cases we provide a compilation of genomic as well as clinical features of this rare subgroup, contributing to a better understanding and eventually to future treatment approaches.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: inrepo02.dkfz.de
700 1 _ |a Schramm, Kathrin
|0 P:(DE-He78)2f592d9d8339bee07cca3956b7472b61
|b 1
|u dkfz
700 1 _ |a Blattner-Johnson, Mirjam
|0 P:(DE-He78)261d2b84aded878003e6e35d18113831
|b 2
|u dkfz
700 1 _ |a Jones, Barbara C
|0 P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4
|b 3
|u dkfz
700 1 _ |a Stark, Sebastian
|0 P:(DE-He78)75cc815aba77c01af41fe20138617e9c
|b 4
700 1 _ |a Balasubramanian, Gnana Prakash
|0 P:(DE-He78)e5bb26ffbde307745ae396c2e829dac5
|b 5
|u dkfz
700 1 _ |a Previti, Christopher
|0 P:(DE-He78)1bae3784eb554a693b0e7ce03a20bdb8
|b 6
|u dkfz
700 1 _ |a Autry, Robert J
|0 P:(DE-He78)50c2928009c788a6a5f3a0708dfb6df5
|b 7
|u dkfz
700 1 _ |a Fiesel, Petra
|0 P:(DE-He78)8de7015af76bd61fb0bc13bb3facb1df
|b 8
|u dkfz
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 9
|u dkfz
700 1 _ |a Reuss, David
|0 P:(DE-HGF)0
|b 10
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 11
|u dkfz
700 1 _ |a van Tilburg, Cornelis M
|0 P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271
|b 12
|u dkfz
700 1 _ |a Pajtler, Kristian W
|0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
|b 13
|u dkfz
700 1 _ |a Milde, Till
|0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
|b 14
|u dkfz
700 1 _ |a Dirksen, Uta
|b 15
700 1 _ |a Kramm, Christof M
|b 16
700 1 _ |a von Bueren, André O
|b 17
700 1 _ |a Munthe-Kaas, Monica C
|b 18
700 1 _ |a Øra, Ingrid
|0 0000-0002-3931-4125
|b 19
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 20
|u dkfz
700 1 _ |a Witt, Olaf
|0 P:(DE-He78)143af26de9d57bf624771616318aaf7c
|b 21
|u dkfz
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 22
|e Last author
|u dkfz
773 _ _ |a 10.1093/noajnl/vdae185
|g p. vdae185
|0 PERI:(DE-600)3009682-0
|n 1
|p vdae185
|t Neuro-oncology advances
|v 7
|y 2025
|x 2632-2498
909 C O |o oai:inrepo02.dkfz.de:294929
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)2f592d9d8339bee07cca3956b7472b61
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)261d2b84aded878003e6e35d18113831
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)75cc815aba77c01af41fe20138617e9c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)e5bb26ffbde307745ae396c2e829dac5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)1bae3784eb554a693b0e7ce03a20bdb8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)50c2928009c788a6a5f3a0708dfb6df5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)8de7015af76bd61fb0bc13bb3facb1df
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)143af26de9d57bf624771616318aaf7c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)551bb92841f634070997aa168d818492
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOL ADV : 2022
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-11-23T11:49:35Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-11-23T11:49:35Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2022-11-23T11:49:35Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-27
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
915 p c |a DFG OA Publikationskosten
|2 APC
|0 PC:(DE-HGF)0002
915 p c |a DOAJ Journal
|2 APC
|0 PC:(DE-HGF)0003
920 2 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatrische Gliomforschung
|x 0
920 0 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatrische Gliomforschung
|x 0
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatrische Gliomforschung
|x 0
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 1
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 3
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 4
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 5
920 1 _ |0 I:(DE-He78)W610-20160331
|k W610
|l Core Facility Omics IT
|x 6
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a I:(DE-He78)W610-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21